Auxilium Pharmaceuticals, Inc. 

(Public, NASDAQ:AUXL)   Watch this stock   
Find more results for AUXL
Nov 18, 2009
Lazard Capital Healthcare Conference - Webcast
Nov 13, 2009
Credit Suisse Healthcare Conference - Webcast
Nov 4, 2009
Oppenheimer & Co. Healthcare Conference - Webcast
Oct 28, 2009
Q3 2009 Earnings Conference Call - Webcast
Oct 28, 2009
Q3 2009 Earnings Release
Sep 21, 2009
UBS Global Life Sciences Conference
Sep 9, 2009
Thomas Weisel Partners Healthcare Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -35.47% -36.92%
Operating margin -35.22% -38.35%
EBITD margin - -36.66%
Return on average assets -29.91% -33.28%
Return on average equity -82.18% -93.24%
Employees 340 -

Address

40 Valley Stream Parkway
Malvern, PA 19355
United States - Map
+1-484-3215900 (Phone)
+1-484-3215999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Discussion Group - Google Finance

Description

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians. The Company’s product, Testim, is a topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, adverse changes in body composition, irritability and poor concentration. The product pipeline of the Company includes XIAFLEX (clostridial collagenase for injection) for the treatment of Dupuytren’s contracture (Dupuytren’s), XIAFLEX for the treatment of Peyronie’s disease (Peyronie’s), XIAFLEX for the treatment of Adhesive Capsulitis (frozen shoulder syndrome), AA4010, treatment for overactive bladder using the transmucosal film delivery system and fentanyl pain product using the transmucosal film delivery system.

Officers and directors

Rolf A. Classon
Chairman of the Board
Age: 64
Bio & Compensation - Reuters
Armando Anido
President, Chief Executive Officer, Director
Age: 51
Bio & Compensation - Reuters
James E. Fickenscher
Chief Financial Officer
Age: 45
Bio & Compensation - Reuters
Jennifer Evans Stacey Esq.
Executive Vice President, General Counsel, Human Resources and Secretary
Age: 44
Bio & Compensation - Reuters
Roger D. Graham Jr.
Executive Vice President - Sales & Marketing
Age: 46
Bio & Compensation - Reuters
Jyrki Mattila M.D., Ph.D.
Executive Vice President, Business Development, Product Development and Technical Operations
Age: 54
Bio & Compensation - Reuters
Anthony DelConte M.D.
Chief Medical Officer
Age: 51
Bio & Compensation - Reuters
Edwin A. Bescherer Jr.
Director
Age: 75
Bio & Compensation - Reuters
Philippe O. Chambon M.D., Ph.D.
Director
Age: 51
Bio & Compensation - Reuters
Alfred Altomari
Director
Age: 50
Bio & Compensation - Reuters